Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported a solid start to 2025, with notable financial improvements and growing momentum in its core business segment.
The company operates through two primary businesses: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business.
The MRD business centers around its flagship clonoSEQ diagnostic test, which is FDA-authorized for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Additionally, clonoSEQ is available as a CLIA-validated laboratory-developed test for other lymphoid cancers, including diffuse large B-cell lymphoma and mantle cell lymphoma. The IM business is focused on the discovery and development of immune-based therapies for cancer and autoimmune diseases.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.